A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs CEVA 101 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2020.
- 28 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.